Research programme: clarithromycin nano-emulsion formulation - ADVENTRX Pharmaceuticals
Alternative Names: ANX-015; BTH 015; SDP-015Latest Information Update: 29 Dec 2021
At a glance
- Originator ADVENTRX Pharmaceuticals
- Class Antibacterials; Macrolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 30 Jan 2007 Preclinical development is ongoing